Skip to main content
Log in

Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules

Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

The antiemetic response and side effects resulting from treatment with methylprednisolone (MPA) given on two different dose schedules were evaluated in 20 women with breast cancer who were undergoing chemotherapy consisting of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). This randomized, crossover, double-blind study compared the antiemetic efficacy of a single dose of 125 mg MPN with that of two such doses. The study demonstrated the superiority of the latter protocol in preventing CMF-induced nausea and vomiting. The rate of antiemetic response to single vs double doses was as to follows: complete protection, 17% vs 30%; partial and minimal protection, 39% vs 55%; and no protection, 44% vs 15% of the courses, respectively (P=0.0087). No difference in the antiemetic response rate was found between the first and the second course. Treatment with MPN was well tolerated, and no difference in the incidence of side effects was found between the single-dose and the double-dose schedule. We recommend the use of two doses of 125 mg MPN as prophylactic antiemetic treatment in breast-cancer patients receiving CMF chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bennet AE, Richi AE (1975) Questionnaires in medicine: a guide to their design and use. Oxford University Press, Oxford

    Google Scholar 

  2. Benrubi GI, Norvell M, Nuss RC, et al. (1985) The use of methylprednisolone and metoclopramide in control of emesis in patients receiving cisplatinum. Gynecol Oncol 21:306–313

    Google Scholar 

  3. Buser K, Joss R, Piquet D et al. (1990) A randomized double-blind comparison of oral Ondansetron and placebo in the prophylaxis of CMF-induced nausea and vomiting. Proc Am Soc Clin Oncol 9: A1269

    Google Scholar 

  4. Chiara S, Campora E, Lionetto R, et al. (1987) Methylprednisolone for the control of CMF-induced emesis. Am J Clin Oncol 10: 264–265

    Google Scholar 

  5. Gez E, Goodman S, Isacson R, et al. (1986) High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer. Oncology 43:173–175

    Google Scholar 

  6. Gez E, Brufman G, Kaufman B, et al. (1989) Methylprednisolone and chlorpromazine in patients receiving cancer chemotherapy: a prospective non-randomized study. J Chemother 1:140–143

    Google Scholar 

  7. Gez E, Sulkes A, Ochayon L, et al (1989) Methylprednisolone versus metoclopramide as an antiemetic treatment in patients receiving adjuvant CMF chemotherapy: a randomized crossover-blind study. J Chemother 1:365–368

    Google Scholar 

  8. Morran C, Smith DC, Anderson DA, et al. (1979) Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomized trial of antiemetics. BMJ 1:1323–1324

    Google Scholar 

  9. Roila F, Basurto C, Minotti V, et al. (1988) Methylprednisolone for prevention of nausea and vomiting in breast cancer patients treated with cyclophosphamide, methotrexate and 5-fluorouracil: a double-blind randomized study. Oncology 45:346–349

    Google Scholar 

  10. Wilcow PM, Fetting JH, Nettesheim KM, et al. (1982) Anticipatory vomiting in women receiving cyclophosphamide, methotrexate and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. Cancer Treat Rep 66:1601–1604

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gez, E., Strauss, N., Vitzhaki, N. et al. Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules. Cancer Chemother. Pharmacol. 30, 229–232 (1992). https://doi.org/10.1007/BF00686319

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686319

Keywords

Navigation